Tibolone and 5α-dihydrotestosterone alone or in combination with an antiandrogen in a rat breast tumour model

European Journal of Cancer

Volumn 38, Issue 3, 2002, Pages 443-448

  Deckers, G H ^a   Verheul, H A M ^a   van Aalst, G B T ^a   Cremers, E A M ^a   de Gooyer, M E ^a   Kloosterboer, H J ^a  

^a NV ORGANON   (Netherlands)

Author keywords

Breast cancer; Dihydrotestosterone; DMBA; Flutamide; Tibolone

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; FLUTAMIDE; PREGNANE DERIVATIVE; TIBOLONE; ANDROGEN RECEPTOR; ANDROSTANOLONE; DRUG METABOLITE; PLACEBO;

ANIMAL; ARTICLE; FEMALE; ORAL DRUG ADMINISTRATION; RAT; SPRAGUE DAWLEY RAT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BREAST CARCINOMA; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FLUTAMIDE; NORPREGNENES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0036007646     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00391-4     Document Type: Article

References (36)

1. Breast cancer and hormonal contraceptives: Collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies
2. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer
3. Role of androgen receptor in human breast cancer
4. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression
5. Influence of underfeeding during 'critical period' or thereafter on carcinogen induced mammary tumors in rats
6. Host factors affecting the growth of carcinogen induced rat mammary carcinomas. A review and tribute to Charles Brenton Huggins
7. Effects of progesterone on mammary carcinogenesis when various doses of DMBA were applied directly to rat mammae
8. Additive inhibitory effects of bromocryptine (CB-154) and medroxyprogesterone acetate (MPA) on dimethylbenz[a]anthracene (DMBA)-induced mammary tumors in the rat
9. Antitumor effects of combination toremifene and medroxyprogesterone acetate (MPA) in vitro and in vivo
10. Inhibitory effect of androgens on DMBA-induced mammary carcinoma in the rat
11. Effects of progestagens and tibolone in in vitro and in vivo tumor models
12. Endocrinological studies with (7α, 17α)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one (Org OD 14)
13. Clinical profile of Org OD 14
14. Pharmacological profile of Org OD 14 in experimental animals
15. Tibolone and its metabolites: Pharmacology, tissue specificity and effects in animal models of tumors
16. Treatment of breast cancer with different antiprogestins: Preclinical and clinical studies
17. Gonadal hormones and breast cancer risk: The estrogen window hypothesis revisited
18. In vitro evaluation of estrogenic, estrogen antagonistic and progestagenic effects of a steroidal drug (Org OD-14) and its metabolites on human endometrium
19. Human endometrial 3β-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of steroidal drugs
20. 4 isomerase type 1 gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13
21. Opposite effects of dehydroepiandrosterone on the growth of 7,12-dimethylbenz (a)anthracene-induced rat mammary carcinomas
22. Combined effects of dehydroepiandrosterone and EM-800 on bone mass, serum lipids and the development of dimethylbenz(A)anthracene-induced mammary carcinoma in the rat
23. Dehydroepiandrosterone inhibits the growth of DMBA-induced rat mammary carcinoma via the androgen receptor
24. Control of estrone sulfatase activity in human breast cells: Effect of tibolone and its metabolites
25. Progestins and breast cancer
26. Tibolone: A compound with tissue specific inhibitory effects on sulfatase
27. Effects of Org OD14 (Livial®) and its metabolites on 17β-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells
28. Effect of Org OD14 (Livial®) and its metabolites on human estrogen sulphotransferase activity in hormone dependent MCF-7 and TD-47D, and the hormone independent MDA-MB-231, breast cancer cell lines
29. Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells
30. The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells
31. Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals
32. Tibolone: A review
33. Livial: A review of clinical studies
34. Mammographic changes in women receiving tibolone therapy
35. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy
36. Effects of tibolone and a continuous combined HRT regimen on mammographic breast density